Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

ASTRAZENECA PLC : Ex-dividend day for interim dividend

share with twitter share with LinkedIn share with facebook
08/13/2020 EDT

An interim dividend is removed today from AstraZeneca PLC's share.



© Factset 2020
share with twitter share with LinkedIn share with facebook
All news about ASTRAZENECA PLC
09/25JOHNSON & JOHNSON, NIKE, ILLUMINA : Stocks That Defined the Week
DJ
09/25Canada's biggest provinces seek clampdown on social gatherings as coronavirus..
RE
09/25Europe takes new action against Apple, Boeing’s 737 MAX flying soon?
09/25What you need to know about the coronavirus right now
RE
09/25EXCLUSIVE : AstraZeneca gets partial immunity in low-cost EU vaccine deal
RE
09/25AstraZeneca gets partial immunity in low-cost EU vaccine deal
RE
09/25Eu paid lower price for astrazeneca vaccine in return for partial liability -..
RE
09/25Astrazeneca granted partial shield against side-effect claims in eu covid vac..
RE
09/25NOVAVAX : initiates late-stage COVID-19 vaccine trial in UK
RE
09/24Pfizer partner BioNTech sees no role for its vaccine in UK challenge trial
RE
More news
Financials (USD)
Sales 2020 26 694 M - -
Net income 2020 3 079 M - -
Net Debt 2020 13 082 M - -
P/E ratio 2020 50,6x
Yield 2020 2,58%
Capitalization 143 B 143 B -
EV / Sales 2020 5,86x
EV / Sales 2021 5,14x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 117,86 $
Last Close Price 109,30 $
Spread / Highest target 42,2%
Spread / Average Target 7,83%
Spread / Lowest Target -39,6%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC12.74%142 957
JOHNSON & JOHNSON-0.14%383 497
ROCHE HOLDING AG5.40%304 339
MERCK & CO., INC.-8.82%209 750
PFIZER, INC.-7.99%200 326
NOVARTIS AG-12.61%190 402